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Abstract: Apoptotic resistance remains a hallmark of glioblastoma (GBM), the most common
primary brain tumor in adults, and a better understanding of this process may result in more
efficient treatments. By utilizing chromatin immunoprecipitation with next-generation sequencing
(CHIP-seq), we discovered that GBMs harbor a super enhancer around the Mcl-1 locus, a gene that
has been known to confer cell death resistance in GBM. We utilized THZ1, a known super-enhancer
blocker, and BH3-mimetics, including ABT263, WEHI-539, and ABT199. Combined treatment
with BH3-mimetics and THZ1 led to synergistic growth reduction in GBM models. Reduction in
cellular viability was accompanied by significant cell death induction with features of apoptosis,
including disruption of mitochondrial membrane potential followed by activation of caspases.
Mechanistically, THZ1 elicited a profound disruption of the Mcl-1 enhancer region, leading to a
sustained suppression of Mcl-1 transcript and protein levels, respectively. Mechanism experiments
suggest involvement of Mcl-1 in the cell death elicited by the combination treatment. Finally,
the combination treatment of ABT263 and THZ1 resulted in enhanced growth reduction of tumors
without induction of detectable toxicity in two patient-derived xenograft models of GBM in vivo.
Taken together, these findings suggest that combined epigenetic targeting of Mcl-1 along with
Bcl-2/Bcl-xL is potentially therapeutically feasible.
Keywords: THZ1; BH3-mimetics; Mcl1; super-enhancer; non-coding regions; epigenome

1. Introduction
The inherent resistance toward cell death is a challenge for glioblastoma therapy, the most
common primary tumor for which no curative therapy currently exists [1–3]. Several types of cell
death have been described, but apoptosis remains pivotal [4–6]. While apoptosis is regulated at several
levels, the mitochondrial regulation is central and is governed by pro- and anti-apoptotic Bcl-2 family
members [7–9]. The executer pro-apoptotic members are BAX and BAK, facilitating the liberation
of cytochrome-c from the mitochondria following dissociation from their anti-apoptotic Bcl-2 family
member interacting partners [9,10]. In contrast, Mcl-1 is a member of the anti-apoptotic fraction of Bcl-2
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proteins, which has been shown to block therapeutic responses in glioblastoma (GBM), e.g., mediating
radiation resistance [11,12]. Mcl-1 interacts with BAK and thereby interferes with the pro-apoptotic
function of BAK. When Mcl-1 is inhibited, BAK is released and may facilitate cell death in concert
with pro-apoptotic BAX [7–9,13]. Aside from Mcl-1, Bcl-2, and Bcl-xL are of interest as well. With the
advent of ABT-737 in 2005, it became feasible to interfere with both Bcl-2 and Bcl-xL and thereby
induce cancer cell apoptosis [7–9,13]. The discovery of ABT-737 followed another compound of the
same class that was named ABT-263, which, in contrast to ABT-737, is orally available, rendering it
clinically more amenable than its predecessor [9]. Nevertheless, researchers sought to develop the
concept even further and reached another milestone with the development of the state of the art
BH3-mimetic, ABT-199 (Venetoclax), a specific inhibitor of Bcl-2 with drastically lower affinity to
Bcl-xL [8]. The fact that ABT-199 received FDA-approval makes it the prototype of a successful clinical
translation following several decades after the original discovery of Bcl-2 in follicular lymphomas as
part of the hallmark translocation between chromosome 14 and 18, which is the key diagnostic criterion
of this hematological neoplasm [14,15]. However, while several tumors respond to this strategy of
blocking Bcl-2/Bcl-xL, others reveal a more resistant phenotype, which in part was attributed to high
levels of Mcl-1.
Targeting Mcl-1 as a treatment strategy has received recent and on-going attention.
For hematological malignancies, small molecule inhibitors remain an appealing strategy, and several
efforts have been launched in this regard [16]. The integration of these inhibitors is lagging behind for
solid malignancies, but there may still be potential promise with early findings related to preclinical
breast cancer models. However, the direct inhibition of Mcl-1 has several pitfalls [17], such as the
fact that these molecules come with a high molecular weight, which, in the context of glioblastoma,
might be cumbersome due to the presence of the blood brain barrier [18,19]. Therefore, alternative
approaches are deemed necessary for the inhibition of Mcl-1.
Non-coding regions of the DNA have received significant attention over the last couple of
years, especially in light of the fact that mutations in the coding genome are insufficient to explain
the entire pathophysiology of tumors and the evolvement of treatment resistance. In this vein,
the enhancer/super-enhancer landscape of tumors has been coined as a driver of tumor growth
and maintenance by facilitating the up-regulation of genes in proliferation, migration, angiogenesis,
and cell death [20]. Moreover, recent research clearly demonstrates that enhancers can be efficiently
targeted by drug compounds that interfere with phosphorylation of RNA-polymerase II (Rpb1) [21,22].
One of these inhibitors is the CDK7/12 blocker, THZ1, that has been shown to interfere with present
and emerging enhancers [21,22]. An earlier study demonstrated evidence that THZ1 exerts killing
activity in GBM model system, although this was only in the context of a single treatment [23]. Here,
we demonstrated that glioblastomas harbor a super-enhancer at the MCL1 locus, which translated to
increase MCL1 levels as compared to normal brain tissue. While suppression of Mcl-1 alone did not
yield in significant apoptosis induction, combined inhibition of Bcl-xL/Bcl-2 and Mcl-1 led to strong
cell killing and a reduction of tumor growth in patient-derived xenograft models in vivo.
2. Results
2.1. Identification of a Super-Enhancer at the Mcl-1 Locus in Glioblastoma Tissues and Cells
We interrogated publicly available datasets on GBM tissues and respective non-neoplastic brain
tissue to study the epigenome related to apoptosis signaling (Figure 1a–c). Following chromatin
immunoprecipitation with next generation sequencing (CHIP-seq) with the H3K27ac antibody, we studied
the presence of enhancers and super-enhancers in GBM tissues and GBM cell cultures, respectively.
We identified 224 and 642 super-enhancers in GBM1 and U87 cells, respectively (Figure 1a). Through this
analysis and in the context of a related pathway analysis (GREAT), we identified a super-enhancer around
the Mcl-1 gene in glioblastoma, which was also identified in several other GBM cultures (Figure 1a–e). It is
noteworthy that, amongst the different “GO Biological Processes,” negative regulation of cell death was
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the most significant pathway to be modulated by the super-enhancer landscape (Figure 1e). While there
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2.2. Pharmacological Inhibition of Super-Enhancers Suppresses Mcl-1 mRNA and Protein Levels
Following emergence of the concept of super enhancers in cancers, the means to target them
effectively were discovered, and the CDK7/12 inhibitor, THZ1, was amongst the most promising
drugs [22]. To this end, we treated established and PDX GBM cultures with THZ1 and harvested
mRNA to probe Mcl-1 transcripts. Given that TP53 is important in mediating apoptosis and that it is
commonly mutated in gliomas, we used three established cell cultures that are either wild-type (U87)
or mutated TP53 (U251 and LN229). Across all the cell lines tested, we detected a reduction of Mcl-1
transcript levels following exposure to THZ1 (Figure 2a). To confirm that these results are not only
relevant to cell lines derived from adult glioblastomas, we probed the KNS-42 pediatric GBM cell line
and following THZ1 treatment detected a suppression of Mcl-1 transcript levels as well (Figure 2a).
We extended our studies to PDX cell cultures using the GBM22 and GBM14 lines (Figure 2a). Akin to
the other cultures, THZ1 suppressed Mcl-1 transcript levels, suggesting that THZ1 appears to be a
strong suppressor of Mcl-1 across a broad array of different GBM model systems.
Through the inhibition of its molecular target CDK7 and likely other targets, such as CDK12, THZ1
affects the phosphorylation of RNA-polymerase II and through this mechanism affects transcription and
the modulation of cis-regulatory elements (Figure 2b–e). In keeping with this notion, we hypothesized
that THZ1 should disrupt the enhancer/super-enhancer landscape of GBM cells, including the Mcl-1
super enhancer. To this purpose, U87 GBM cells were treated with DMSO or THZ1. Thereafter,
chromatin was isolated and subjected to CHIP with an antibody against H3K27ac followed by next
generation sequencing. Following computational analysis, we focused on the super-enhancer landscape.
While we noted a strong presence of super enhancers in DMSO exposed U87 GBM cells, THZ1 potently
suppressed the presence/enrichment of H3K27ac at super enhancers, in keeping with the hypothesis
that THZ1 decommissioned super enhancers broadly in GBM cells (Figure 2b–d).
We compared low expressing Mcl-1 cells (astrocytes) with two GBM cells cultures (GBM22 and
LN229) in the context of a CHIP-qPCR assay around the Mcl-1 locus (Figure S1a,b). In accordance with
the Mcl-1 mRNA levels, we found increased enrichment in LN229 and GBM22 cells as compared to the
astrocytes (Figure S1a,b). Next, we narrowed the range and focused on the genetic location around
the MCL1 locus. We found that, following DMSO exposure, the enrichment of H3K27ac was highly
evident, in keeping with the anatomy of an active enhancer. In contrast, we detected a disruption of
the Mcl-1 super-enhancer complex following treatment with THZ1 (Figure 2d). In addition to the
CHIP-seq analysis, we performed CHIP-qPCR in an established cell culture (LN229) and one PDX
(GBM22) line (Figure S1c). In analogy to the experiment performed in U87 GBM cells, LN229 and
GBM22 were treated with THZ1 for 24 h, harvested, and subjected to CHIP with the same antibody
against H3K27ac, but in addition, we utilized an IgG control antibody as well. Following preparation,
real-time PCR analysis proceeded with a primer pair that amplifies a region within the Mcl-1 locus.
In both LN229 and GBM22, we detected a strong signal of H3K27ac marks within the Mcl-1 target
region, whereas the IgG control yielded a significantly weaker signal, suggesting specific binding of
H3K27ac at this location (Figure S1c). Importantly, THZ1 displaced H3K27ac marks from this region
in both LN229 and GBM22 treated samples, in keeping with potential epigenetic disruption of the
epigenetic landscape of the MCL1 locus and the CHIP-seq analysis performed in U87 GBM cells.
These observations are in full agreement with the transcriptional suppression of Mcl-1 by THZ1 as
shown in the real-time PCR analysis. To confirm that THZ1 is indeed acting on target, established (U87)
and PDX (GBM22) GBM cells were exposed to increasing concentrations of THZ1 for 24 h. Thereafter,
protein lysates were analyzed for the expression of phosphorylated Rpb1 (CDK7 and likely other
targets), total Rpb1, and Mcl-1 (Figure 2e and Figure S2). Irrespective of the GBM culture tested, we
detected a dose-dependent decrease of phosphorylated Rpb1 levels, which appeared to correlate with
a drop of Mcl-1 protein levels (Figure 2e and Figure S2). These results are consistent with a model,
proposing a direct correlation between transcriptional inhibition and concerted decline in Mcl-1 protein
levels, in keeping with the mechanism of action by THZ1.
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Next, we evaluated the protein levels of the most relevant anti- and pro-apoptotic Bcl-2 family
members, including Mcl-1, Bcl-2, Bcl-xL, and Noxa. To this purpose, we focused again on the earlier
cell cultures used for the real-time PCR analysis, ensuring a broad range of different type of tumors.
All cell cultures were treated with increasing concentrations of THZ1 and, following incubation for
24 h protein, they were harvested. Thereafter, standard western blotting was employed. Independent
of the TP53 status, we noted a dose dependent decrease of Mcl-1 in U251, U87, and LN229 GBM cells
(Figure 2f,g). In the PDX lines, this effect was even more pronounced than in the established GBM
cell cultures (Figure 2f,g and Figure S1d). Consistently, we also detected a suppression of Mcl-1 in
the pediatric GBM cell line, KNS-42 (Figure S1d). These results demonstrate potent Mcl-1 protein
level suppression by THZ1 across all relevant model systems tested. Mcl-1 interacts with a number
of proteins, but with regard to apoptosis induction, it appears certain that Noxa is amongst the most
relevant partners given that Noxa antagonizes the ability of Mcl-1 to block apoptosis by facilitating
release of BAK from Mcl-1. Therefore, the ratio between Noxa and Mcl-1 is an indicator for the
apoptotic threshold of tumor cells. To this end, we determined Noxa protein levels in the current cell
cultures following exposure with increasing concentrations of THZ1. Across the cell cultures tested
(established, PDX, and pediatric GBM cultures), we found that, in most instances, Noxa levels declined
following THZ1 exposure but significantly less than Mcl-1 protein levels. We also checked the protein
levels of Bcl-xL given its significant implication on the viability of solid tumors. We found that THZ1
suppressed this anti-apoptotic Bcl-2 family member as well, but in contrast to Mcl-1, much higher levels
of THZ1 were necessary for the detection of this effect. We concluded with the analysis of Bcl-2 protein
levels, the most prominent member within the family, and found that THZ1 also suppressed Bcl-2
protein levels (Figure 2f). It is further worth mentioning that, while the PDX lines displayed a reduction
of Bcl-2 levels following THZ1 treatment, the effect on Mcl-1 appeared to be more pronounced.
2.3. The Super-Enhancer Blocker, THZ1, Sensitizes GBM Cells to the Cytotoxic Effects of BH3-Mimetics,
and Attenuates ABT263 Mediated Up-Regulation of Mcl-1
Given the suppression of Mcl-1 by THZ1, it was tempting to speculate whether THZ1 and
BH3-mimetics would induce synergistic reduction in cellular viability in GBM model system given
the long list of evidence that Mcl-1 is the primary mediator of resistance for BH3-mimetics that target
either Bcl-2 or Bcl-xL. To this purpose, established GBM cells (U87, U251, and LN229) were treated
with ABT263, THZ1 or the combination of both. Consistent with previous observations, we noted
some reduction in cellular viability by ABT263 (Figure 3a). Similarly, but slightly more pronounced,
we also detected a loss in viability following THZ1 treatment. Notably, when the two compounds
were combined, we detected a synergistic reduction in cellular viability (CI < 1.0). Notably, the U87
cells displayed the most significant engagement of synergistic growth reduction with an astonishing
low CI value (Figure 3b). We further extended these experiments to a range of different PDX lines,
including GBM22, GBM12, GBM14, GBM123, and GBM43. Akin to the established GBM cells, we noted
a synergistic growth reduction when ABT263 and THZ1 were combined, which was most pronounced
in GBM12 and GBM14 cells with very low CI values, mirroring the findings obtained in the U87
cells (Figure 3a–c and Figure S3a–c). Remarkably, this effect was seen at low nano-molar dosages for
both ABT263 and THZ1, suggesting potential translatability. Despite this truly remarkable synergy,
the GBM22 and GBM123 cells also revealed synergistic growth reduction following treatment with
the combination of ABT263 and THZ1. Regarding the pediatric GBM line, we detected a synergistic
growth reduction by the combination treatment in KNS-42 cells as well (Figure S3d). Finally, we asked
whether stem-like GBM cells would be affected by the combination treatment because these cells
have been shown to be pivotal for tumor recurrence, and killing them off may lead to a prolongation
of tumor therapeutic responses. To this purpose, we embarked on NCH644 stem-like GBM cells
that, from their isolation, were grown under neuro spheres conditions and have been relatively well
characterized (Figure S3e). Akin to the cell lines before, we noted single-agent activity by both ABT263
and THZ1. The combination treatment resulted in significant synergistic reduction cellular viability,
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Next, we sought out to determine how the combination treatment of ABT263 and THZ1 were
to affect the expression levels of the Bcl-2 family members since ABT263 is known to modulate in
particular the levels of Mcl-1 and thereby causing a paradoxical partial drug-mediated resistance.
Using the same panel of cell lines, we found that ABT263 increased Mcl-1 levels in U251, LN229,
and GBM22 cells and that this up-regulation was suppressed by THZ1 (Figure 3d,e).
2.4. The Combination Treatment of ABT263 and THZ1 Elicits Enhanced Activation of a Cell Death with
Features of Apoptosis
To accomplish the most efficient treatment against GBM, it is desirable to develop therapies that
not only stall proliferation but instead induce cell death, ultimately conferring the potential to such
treatments to elicit tumor regression. Given that BH3-mimetics usually elicit their anti-tumor effects by
induction of apoptosis, we hypothesized that the combination treatment of ABT263 and THZ1 would
lead to strong cell death induction with features of apoptosis. To this purpose, we tested established
and PDX lines and treated them with ABT263, THZ1, or a combination. Following incubation,
the cells were subjected to staining with annexin V/PI staining, a classical methodology to measure
apoptosis. The results of the multi-parametric flow cytometry showed cell death in response to single
agent therapy. However, the combination treatment was much more efficient to induce cell death,
in keeping with the hypothesis that the synergistic reduction in cellular viability is likely to be largely
mediated through enhanced cell death (Figure 4a,b, and Figure S4a,b). In addition to annexin V
staining, we assessed DNA fragmentation by flow cytometry as well and found that the combination
treatment led to enhanced increase of cells in the sub-G1 fraction, indicative of a cell death with
apoptotic features (Figure 4c and Figure S4c). The classical features of intrinsic apoptosis are the loss
of mitochondrial membrane potential that is succeeded by activation initiator and effector caspases
followed by cleavage of caspase substrates, such as alpha-fodrin or PARP. To this end, established GBM
cells (U87, U251, and LN229) were treated with ABT263, THZ1 or the combination of both and after
treatment stained with TMRE (Figure 4d and Figure S5a,b). The flow cytometric analysis yielded some
loss of mitochondrial membrane potential, resulting from single treatment administration. Notably,
the combination treatment was much more potent than single treatments or vehicle. We confirmed
these findings in PDX lines as well (Figure S5a,b). The final execution of apoptosis, be it extrinsic or
in the current case intrinsic, takes place at the activation of caspases. To assess caspase activation,
we utilized a well-accepted surrogate that is caspase cleavage detection by western blotting. U87
and U251 GBM cells were treated with vehicle, ABT263, THZ1, or a combination, and thereafter,
protein lysates were analyzed for PARP, caspase 9, and cleaved caspase-3 levels. We found that the
combination treatment led to a depletion/cleavage of PARP levels in both cell lines tested (Figure 4e
and Figure S5c). We noted a depletion of total caspase 9 levels with enhanced appearance of cleavage
productions of both caspase 9 and caspase 3, suggesting activation of the caspase cascade. Similar
findings were obtained in LN229 GBM cells (Figure S5d).
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In recent years, excitement has been generated by the emergence of selective BH3-mimetics,
enabling to target just one of the Bcl-2 family members exclusively. We hypothesized that, given earlier
findings, the combination treatment of BH3-mimetics and THZ1 would likely work best through
Bcl-xL inhibition given its role in solid malignancies. To this purpose, U87 and U251 cells were treated
with vehicle, WEHI-539 (selective Bcl-xL inhibitor) [25], THZ1, or a combination. Thereafter, cellular
viability was analyzed in the context of a synergism analysis through isobologram computation,
demonstrating synergistic growth reduction (Figure S6a–c). In a parallel experiment, we utilized
ABT-199 (a selective Bcl-2 inhibitor) in lieu of WEHI-539. Consistently, we noted synergistic growth
reduction by the combination treatment of ABT-199 and THZ1 (Figure S6d–f). Multi-parametric flow
cytometric following labeling with AnnexinV/PI yielded enhanced cell killing by the combination
treatment of WEHI-539 and THZ1 when compared to vehicle or single treatment (Figure 4f and Figure
S6g). Next, we determined the expression levels of the Bcl-2 family of proteins following treatment
with WEHI-539 and THZ1. We found that the combination treatment reduced the Mcl-1 protein
levels and that the ratio between Noxa and Mcl-1 was elevated, in keeping with enhanced cell death
induction. We also noted a suppression of Bcl-2 and Bcl-xL protein levels following incubation with
the combination treatment (Figure S6h). Finally, we studied the effects of the combination treatment of
WEHI-539 and THZ1 on caspase cleavage. Akin to the combination treatment of ABT263 and THZ1,
the selective BH3-mimetic, WEHI-539, combined with THZ1 exerted significant cleavage of initiator
caspase-9 and effector caspase-3 accompanied by the appearance of the 89 kDa PARP cleavage product
(Figure S6i). These results suggest that selective BH3-mimetics synergize with THZ1 to induce cell
death with apoptotic features, and it is encouraging to note that even ABT199 (which is FDA-approved)
appeared to be effective as well.
2.5. Suppression of Mcl-1 by THZ1 Is Sufficient and Necessary to Sensitize GBM Cells for
BH3-Mimetic-Mediated Cell Death
Next, we determined the role of Mcl-1 and its impact to mediate the survival of established and
patient-derived GBM cultures. Despite the presence of novel BH3-mimetics that selectively target
Mcl-1, we decided to utilize siRNAs to assess the impact of Mcl-1 on cell-death induction in both
U87, LN229, and U251 GBM cells, representing a range of different genetic backgrounds. Following
transfection with non-targeting or Mcl-1 specific siRNA and validation of knockdown, the GBM cells
were subjected to treatment with vehicle or ABT263. Thereafter, the sub-G1 fraction was assessed
by flow cytometric analysis (Figure 5a,b and Figure S7a). While silencing of Mcl-1 mediated a mild
increase in apoptosis, ABT263 enhanced the killing effect further as compared to transfection with
non-targeting siRNA, which was validated in PDX lines as well (Figure 5a,b). We went on to confirm
that silencing of Mcl-1 will enhance cleavage of caspases and caspase substrates following treatment
with ABT263. To this purpose, LN229 cells were transfected with non-targeting or two Mcl1-specific
siRNAs. Thereafter, treatment with ABT263 was performed and the protein lysates were analyzed for
the cleavage of caspases. As anticipated, silencing of Mcl-1 sensitized for ABT263 mediated cleavage
of caspases and PARP in LN229 GBM cells (Figure 5c,d).
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by ABT263 and THZ1. To this end, we harnessed a two‐pronged strategy, involving both silencing and
over‐expression of Mcl‐1. We found that in the presence of ABT263 silencing of Mcl‐1 drastically
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and over-expression of Mcl-1. We found that in the presence of ABT263 silencing of Mcl-1 drastically
reduced the viability of GBM cells and that this effect was not further enhanced when THZ1 was
present, indicating that Mcl-1 is sufficient to explain how THZ1 sensitizes for BH3-mimetic mediated
reduction in viability (Figure S7b). Finally, we tested whether overexpression of Mcl-1 would rescue
the killing effects mediated by the combination treatment of ABT263 and THZ1. To this purpose,
we transiently transfected a control plasmid or Mcl-1 cDNA into LN229 and U251 GBM cells given that
these cells tolerate transient transfection reasonably well (Figure 5e). Following transfection, the GBM
cells were either treated with vehicle or incubated with the combination treatment of ABT263 and
THZ1. Thereafter, cells were subjected to analysis of DNA-fragmentation (sub-G1 fraction) by flow
cytometry (Figure 5e). We found that over-expression of Mcl-1 cDNA partially rescued from killing by
the combination treatment, suggesting that Mcl-1 is both sufficient and necessary for the combination
treatment to exert its anti-glioma effects (Figure 5e). Nota bene, these findings also implicate that,
while Mcl-1 is truly involved, it appears valid to conclude that downregulation of anti-apoptotic Mcl-1
is not the only factor required for the combination to drive apoptosis.
It would be of interest to elucidate the underlying mechanisms how THZ1 (a CDK7 inhibitor)
would disrupt the Mcl-1 super-enhancer region, which would likely involve interference of CDK7
or potential other CDKs. To address this vital question, we utilized a structurally inactive THZ1R
compound that has been chemically modified such that it no longer binds to CDK7, which, in turn,
will not inhibit RNA-polymerase II activity. Therefore, it would not interfere with the super-enhancer
landscape and in consequence does not affect Mcl-1 levels. To this end, we hypothesized that THZ1R
would not enhance the killing effect of BH3-mimetics. We harnessed the GBM22 PDX line that was
treated with vehicle, ABT263, THZ1, or THZ1R or the respective combination of ABT263 and THZ1 and
ABT263 and THZ1R. While the combination treatment of ABT263 and THZ1 synergistically reduced the
cellular viability, this effect was essentially abated when THZ1R was used in lieu of THZ1, suggesting
that CDK7 inhibition might be important for THZ1 to enhance the killing effects of BH3-mimetics
(Figure S7c). These results led us to hypothesize that the silencing of CDK7 might be sufficient to
sensitize GBM cells to the cytotoxic effects of BH3-mimetics (Figure S8a–d). Silencing of CDK7 had
little effect on the sub-G1 fraction of GBM22 cells as compared to transfection with non-targeting
siRNA. However, knockdown of CDK7 led to some mild enhancement of ABT263-mediated increase of
apoptosis (Figure S8a–d). These results suggest that the sensitization effect by THZ1 to BH3-mimetics
involves additional targets other than the inhibition of CDK7.
2.6. The Combination Treatment of ABT263 and THZ1 Exerts Enhanced Anti-Glioma Activity in
Patient-Derived Xenograft In Vivo without Significant Organ Toxicity
We utilized two PDX models system in mice to validate whether or not the combination treatment
of THZ1 and BH3-mimetics would lead to enhanced reduction of tumor growth without significant
toxicity, given that such successful experiments would constitute the basis for further translational
development for this treatment strategy (Figure 6a–d). To this purpose, we implanted the GBM12 PDX
lines in the subcutis of Nu/Nu mice. Following establishment of tumors, four groups were formed,
and treatment was initiated with vehicle, ABT263, THZ1, or a combination of both. While THZ1 exerted
little growth reduction in tumor growth, ABT263 reduced the size of tumors. Notably, the combination
treatment of ABT263 and THZ1 led to an enhanced suppression of tumor volumes as compared to
vehicle and single treatments (Figure 6a,b). To ensure that the effects are not restricted to one model
system, we extended our studies to another PDX model in vivo (GBM43) (Figure 6c,d). Resembling the
findings obtained in the GBM12 model, we found that the combination treatment led to a significant
growth reduction of tumors as compared to single treatments. On the histopathological level, we noted
that the combination treatment resulted in substantial disarray of tumor morphology with a reduction
in cellular density, appearance of cell death, and a reduced occurrence of mitotic figures (Figure 6e).
To further confirm the appearance of cell death, we performed TUNEL staining on the tumor slides
from the various groups and noted an increase of labeled nuclei/cells in slides from tumors exposed to
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3. Discussion
The landscape of the epigenome is emerging as a potential target for the therapy of cancers [26–29].
To date, there are numerous histone-modifying enzymes that can be categorized in writers, erasers,
and readers. With regard to these chemical modifications, acetylation and methylation may be
the most abundant ones when considering the currently available literature [30]. The differences
in post translational modifications of histones establishes an epigenetic code and orchestrates the
accessibility of the chromatin, thereby regulating transcription [29]. The concept of super-enhancers
has recently emerged and is an interesting model to provide an epigenetic explanation as to why certain
pathways are up-regulated in cancers. Enhancers are regulators of gene expression that are several
kilo bases down- or up-stream of the transcriptional start site to control transcription (loop formation)
and their disruption may be an emerging therapeutic opportunity [30]. Here, we found that Mcl-1
expression correlated with the presence of a super-enhancer region in glioblastoma models, providing
an explanation why this protein is increased in gliomas.
The wealth of epigenetic inhibitors has enabled researchers to target the epigenome, i.e., enhancers.
Considering the available literature, targeting the enhancer landscape may be accomplished by at least
three different classes of inhibitors targeting bromodomain protein 4 (BRD4), histone deacetylases
(HDAC), e.g., panobinostat or romidepsin, and CDK7, e.g., THZ1 [31,32]. Concerning other studies,
it appears that THZ1 or recently developed derivatives are frequently used to decommission super
enhancers. For instance, it has been recently shown that exposure of tumor cells to clinically validated
kinase inhibitors results in reprogramming of the enhancer landscape, driving resistance to therapy [33].
This concept was exemplified in BRAF V600E mutated melanoma models exposed to kinase inhibitors,
conferring immediate clinical relevance on these findings. Regarding other oncogenes, a recent
intriguing observation was made related to a skull-based tumor called chordoma [34]. These neoplasms
express high levels of a transcription factor, called brachyury (encoded by the TBXT gene), and critically
rely on it for survival, thereby qualifying it as a marker and equally relevant as a therapeutic target.
Considering the generally accepted notion that transcription factors are challenging to target, it was
a welcome finding that the TBXT gene is surrounded by a super-enhancer in chordoma, thereby
rendering this molecule targetable by epigenetic inhibitors, which in that study was accomplished
through THZ1 [34].
Super enhancers appear to regulate the immune system, since it was recently shown that PD-L1
is encased by a super-enhancer in breast cancer cell lines [35]. Consistent with this observation, it is
not surprising that a recent study found that THZ1 is capable of enhancing the efficacy of immune
therapy in model systems of lung cancer [36]. Our research findings complement these earlier studies
in that we utilized THZ1 to disrupt the Mcl-1 super enhancer. By conducting CHIP-seq (H3K27ac)
in vehicle and THZ1-treated GBM cells, we confirmed that the Mcl-1 super-enhancer was indeed
disrupted by THZ1. In turn, THZ1 potently suppressed Mcl-1 transcript and protein levels, respectively.
As expected, this was accompanied by reduced phosphorylation of RNA-polymerase II. In agreement
with prior publications, we noted a total reduction of RNA-polymerase II following THZ1 treatment
as well [37,38]. It is noteworthy that only a moderate amount of cell death was induced by THZ1 in
keeping with our notion that silencing of Mcl-1 itself is not particularly efficacious to induce cell death
in our model systems tested. However, other model systems have shown different responses to THZ1,
such as certain non-solid malignancies [37]. We recognized that THZ1 also down-regulated the protein
levels of Bcl-xL, but as stated, much higher concentrations of THZ1 were necessary. The most likely
explanation of this phenomenon may be due to the fact that Mcl-1 has a rather short half-life [7,39–41],
and therefore, changes in expression may become apparent much quicker as compared to proteins that
are more stable. We also acknowledge that likely additional targets other than CDK7 are involved in
the effects elucidated by THZ1, e.g., such as CDK12.
Given the limited cell death induction by THZ1, we asked whether the killing efficacy of this
compound might be enhanced in the presence of BH3-mimetics, such as ABT263. This hypothesis
largely emerged from the fact that THZ1 suppressed Mcl-1 protein levels and that drugs that lower
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Mcl-1 levels have commonly been associated to enhance the efficacy of BH3-mimetics that target either
Bcl-2, Bcl-xL, or both [7,9,42–46]. Consistently, we found that THZ1 and BH3-mimetics synergistically
reduced the viability of GBM cells across a broad range of different model systems of human GBM.
Our findings are in line with earlier ones obtained by another group. They reported that ABT263 and
THZ1 reduced the viability of cholangiocarcinoma cells in a synergistic manner [47]. Interestingly,
forced expression of Mcl-1 partially counteracted the killing effect by the combination, establishing
the overall concept that Mcl-1 is sufficient and necessary for the combination treatment to exert its
effects in GBM cells. Our focus mostly rested on the BH3-mimetic ABT263 given its inhibitory effect
on Bcl-xL, since Bcl-xL has been shown to be relevant for counteracting apoptosis, especially in solid
malignancies [17]. Consistently, the BH3-mimetic, ABT199, was slightly less efficient in line with its
target, Bcl-2 that has been coined to be not as relevant for the survival of solid tumors as compared to
Bcl-xL. Whether for instance selective Mcl-1 inhibitors would synergize with THZ1 is an interesting
question, but given that our focus rested on the ability of THZ1 to suppress Mcl-1, we did not address
this question. For instance, it may be possible that, given that THZ1 down-regulates Mcl-1 and thereby
depletes the actual drug target, the inhibitor may become less effective.
Translational cancer research requires the critical in vivo assessment of drug compounds, given that
in vitro results are insufficient for a valid conclusion as to whether or not a certain treatment may
show promise as a novel therapy in cancer [48,49]. We assessed the combination treatment of
BH3-mimetics and THZ1 in heterotopic PDX models in mice and found that the combination treatment
exerted enhanced tumor growth when compared to single treatments without induction of toxicity.
A limitation of the current work is that our studies did not include orthotopic in vivo studies, given that
the microenvironment and the blood brain barrier might interfere with the efficacy of the treatment.
These results are in keeping with earlier drug combinations involving BH3-mimetics [7,9,42–46].
4. Materials and Methods
4.1. Cell Cultures and Growth Conditions
GBM22, GBM123, GBM14, and GBM12 were obtained from the Mayo Clinic Brain Tumor
Patient-Derived Xenograft National Resource (Mayo Clinic, Rochester, MN, USA). U251 cell line was
obtained from Sigma (St. Louis, MO, USA). U87 and LN229 were purchased from the American Type
Culture Collection (Manassas, VA, USA). KNS42 was purchased from Riken BioResource Research
Center (Ibaraki, Japan). Cells were cultured in DMEM medium (Fisher Scientific (Waltham, MA, USA),
MT10013CV) containing 10% FBS (Gemini, NY, USA, FBS002) and 100 µg/mL of primocin (Invivogen,
CA, USA, ant-pm-1). For the experimental conditions, cells were cultured in DMEM containing
1.5% FBS and primocin. NCH644 stem-like glioma cells were obtained from Cell Line Services
(CLS, Heidelberg, Germany) and were cultured in GBM-MG from Cell Line Services (CLS, Heidelberg,
Germany, 820403) for both maintenance and experiments. All cell lines were incubated at 37 ◦ C in an
atmosphere containing 5% CO2 .
4.2. Reagents
ABT-263 (S1001) and THZ1 (S7549) were purchased from Selleckchem (Houston, TX, USA).
WEHI-539 (A3935) and ABT-199 (A8194) were purchased from APexBio Technology (Houston, TX,
USA). All chemicals were dissolved in DMSO to yield a 10 mM stock solution.
4.3. Real-Time PCR Analysis
Cells were harvested and extracted mRNA using the miRNAeasy Mini Kit (QIAGEN, Germantown,
MD, USA, 217004) following the company’s instructions. After extracting mRNA, reverse-transcription
(cDNA synthesis kit (Quantabio 101414-106), and real time PCR (SYBR green RT-PCR reagents kit
(Quantabio, Beverly, MA, USA, 101414-276) were used. The condition for the real-time PCR machine
(Quantabio) is as follows: 95 ◦ C for 10 min, 40 cycles of 95 ◦ C for 15 s, 60 ◦ C for 30 s, and 72 ◦ C for 30 s.
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The fold changes were calculated based on 18S in the threshold cycle (Cq). The sequence primers are
shown in Table 1.
Table 1. Primers for real-time PCR.
Gene

Forward Sequence

Reverse Sequence

18S

AGTCCCTGCCCTTTGTACACA

GATCCGAGGGCCTCACTAAAC

Mcl1

CCAAGAAAGCTGCATCGAACCAT

CAGCACATTCCTGATGCCACCT

ChIP-Mcl1-R1

ATGTCGCCCGAAGAGGAGCTGGACG

CAGCGACTGCCGGTACAACTCGTCC

4.4. Chromatin Immunoprecipitation (CHIP) Sequencing
Chromatin immunoprecipitation (CHIP) of DMSO treated and THZ1 treated samples were
performed with H3K27ac (CST 4535, 10 µL/sample) or Rabbit IgG (CST 2729, 2 µL/sample) following
the company’s instructions (SimpleChIP® Enzymatic Chromatin IP KiT (Magnetic Beads), Cell Signaling
Technology (CST), Danvers, MA, USA, 9003). ChIP DNA was assessed for quality by real-time PCR
analysis before sequencing. After next-generation sequencing library preparation, the samples were
run on an Illumina HiSeQ instrument (HiSeq 4000 (Genewiz, NJ, USA); single read 50 bp (SR50)).
4.5. Computational Analysis of CHIP Sequencing Data
The fastq files were aligned to the human genome (hg38) with bowtie2 followed by peak calling
and generation of bedgraph files, utilizing the MACS2 tool [50]. The bedgraph files were converted to
bigwig files to display them in the integrated genome browser (IGB). For the generation of heatmaps and
plot profiles, we used deeptools [51]. To generate the matrix for heat map generation, computematrix
was used, and the output options were assigned as reference-point based. The heat maps and
the graphical representation of super-enhancers were generated with plotheatmap and plotprofile,
respectively. Regarding the enhancer analysis, we employed HOMER-software (v4.11, 10-24-2019) [52],
which relies on a modified strategy derived from ranking of super-enhancers (ROSE). In short, larger
peaks were stitched together within a distance of 12.5 kb. These regions are then scored and ranked.
All enhancers that lie above the defined threshold slope of 1.0 are defined as super enhancers. Super
enhancers were functionally analyzed through the genomic regions enrichment of annotations tool
(GREAT) and assigned GO-terms related to the biological processes most likely governed by these
cis-regulatory elements. The raw and processed files (U87 treated with DMSO or THZ1 for 24 h) were
deposited in GEO (GSE150986) (this study). The underlying data for the super-enhancer analysis
shown in Figure 1a was downloaded from GEO (GSE119755). The underlying data for GBM tissues
and the normal brain were downloaded from GEO (GSE101148).
4.6. Cell Viability Assays
The determination of cellular viability of the various GBM cells occurred in 96-well plates following
treatments. We used a luminescence method (CellTiter-Glo® assays) in accordance with instructions
manual (Promega (Madison, WI, USA), G7571). To determine drug synergism the median-effect
equation (Chou—Talalay) was employed (isobolograms and the combination index (CI)) [53].
4.7. Flow Cytometry
Following the various treatments of GBM cell cultures, staining was performed in accordance with
the manufacturers’ instructions. Annexin V Apoptosis Detection Kit (BD Pharmingen (Franklin Lakes,
NJ, USA), BD 556419) was used to detect apoptosis. Propidium Iodide (PI)/RNase Staining Solution
was employed (Cell Signaling Technology (Danvers, MA, USA), CST 4087S) to detect the subG1
fraction. TMRE staining (Mitochondrial Membrane Potential kit (CST 13296S)) was conducted to detect
mitochondrial membrane potential. Collected data was analyzed by FlowJo software (version 10.6.2;
Tree Star, Ashland, OR, USA).
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4.8. Transfections of siRNAs and cDNA Plasmid Constructs
For overexpressed experiment, cells were transfected using Lipofectamine 3000 (Invitrogen,
San Diego, CA, USA) and harvested after 24 h after transfection. pcDNA-3 and pcDNA3-hMcl1
(Addgene 25375) were purchased from Addgene (Watertown, MA, USA). For knocked down experiment,
cells were transfected by using Lipofectamine RNAiMAX (Invitrogen (Carlsbad, CA, USA), 13778075) for
72 h in accordance with the manufacturers’ instructions. Non-Targeting siRNA-pool (D-001810-10-20),
siMcl1 pool (L-004501-00-0005), siMcl1-3 (J-004501-16-0002), siMcl1-4 (J-004501-17-0002), and siCDK7
pool (L-003241-00-0005) were purchased from Dharmacon (Lafayette, CO, USA).
4.9. Western Blot Analysis
Cells were lysed in the laemmli buffer (Biorad) containing 1X protease and phosphatase inhibitor
cocktail (Thermo Fisher, Waltham, MA, USA, 78440). Cell lysates were run on a 4–12% SDS PAGE
gel (Invitrogen NP0321BOX), the proteins were transferred to a PVDF membrane, and the membrane
was blocked with 5% skim milk (VWR (Bridgeport, NJ, USA) 97063-958) in TBST (0.1% Tween20)
and probed with target antibodies. Primary antibody incubations were performed overnight at 4 ◦ C.
Antibodies were used Rpb1 (CST 14958), p-Rpb1 (CST 4735), PARP (CST 9532; 1:500), cCP9 (CST 7237;
1:500), cCP3 (CST 9665; 1:500), Mcl-1 (CST 5453; 1:500), Bcl-xL (CST 2764; 1:500), Bcl-2 (CST 4223; 1:500),
Noxa (Calbiochem (Burlington, MA, USA) OP180, clone 114C307; 1:500), β-actin (Sigma Aldrich A1978,
clone AC15; 1:2000). The HRP linked secondary antibodies were from Santa Cruz Biotechnology Inc.
The target protein was detected on the Azure (C300) imaging system. In selected cases, the protein
capillary electrophoresis (Protein Simple (San Jose, CA, USA) SM-W004) was used. The following
antibodies were applied Mcl-1 (CST 5453; 1:25), Bcl-xL (CST 2764; 1:25), Bcl-2 (R&D System, MN, USA,
MAB827; 1:25), Noxa (Calbiochem OP180, clone 114C307; 1:25), and Vinculin (Abcam (Cambridge,
MA, USA) ab129002, 1:500).
4.10. Subcutaneous Xenograft Model
GBM12 and GBM43 glioblastoma patient-derived xenograft (PDX) tumors were injected into the
flanks of 6–8-week-old Nu/Nu mice. After tumors were formed, the mice were randomly assigned into
four treated groups: vehicle, ABT-263 (75 mg/kg), THZ1 (10 mg/kg), or ABT-263 and THZ1. Drugs were
dissolved in DMSO, Kolliphor EL (Sigma, 61791-12-6), Ethyl Alcohol 200 Proof (Pharmco-Aaper, 64-17-5)
and PBS at the following ratio: 10:32:8:50 (v/v/v/v). Tumor and weight measurements were performed
three times a week, followed by intraperitoneal administration of the compounds. The length and
width of tumors were calculated based on the formula: (length × width2 )/2.
4.11. TUNEL and Ki67 Staining
The tumors were fixed in 4% formaldehyde (Thermo Fisher 28908) for 24 h and embedded in
paraffin. Following dewaxing and rehydration, the tumors were exposed to proteinase K (Agilent Dako,
S3020). To detect apoptosis, the processed slides were exposed to TUNEL reaction mixture and the
reaction was terminated in the converter peroxidase solution. The chromogen, diaminobenzidine,
was employed for visualization of the TUNEL-reaction. Background nuclear staining was established
with hematoxylin. To detect cell proliferation, the processed slides were incubated with Ki67 antibody
(Agilent Dako, GA626).
4.12. Statistical Analysis
Statistical significance was assessed by Student’s t-test or ANOVA (for multiple comparison)
using Prism 8 (GraphPad, La Jolla, CA, USA). A p ≤ 0.05 was set as the level of statistical significance.
* p < 0.05, ** p < 0.01, ***/**** p < 0.001, n. s. indicates not significant.
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4.13. Study Approval
All procedures were in accordance with Animal Welfare Regulations and approved by
the Institutional Animal Care and Use Committee at the Columbia University Medical Center
(AC-AABC6505).
5. Conclusions
Based on our findings, we conclude that non-coding DNA elements are involved in mediating
resistance to intrinsic apoptosis in model system of human GBM, which is exemplified by the
identification of a super-enhancer, spanning the MCL1 locus. Disruption of the Mcl-1 super enhancer
through THZ1 sensitizes a broad array of GBM cells to the cytotoxic effects by broad and selective
BH3-mimetics in vitro and in vivo. These findings also bear translational relevance given that both
CDK7 inhibitors and BH3-mimetics have either reached clinical testing or are even FDA-approved.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/8/2137/s1,
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